Literature DB >> 35091777

Mortality associated with Behçet's disease in France assessed by multiple-cause-of-death analysis.

Emmanuelle David1, Mathieu Fauvernier2,3, David Saadoun4,5, Mathieu Gerfaud-Valentin1, Delphine Maurcort-Boulch2, Pascal Sève1,6, Yvan Jamilloux7,8.   

Abstract

OBJECTIVES: To examine the mortality rates and causes of death among French decedents with Behçet's disease (BD).
METHODS: Data collected between 1979 and 2016 by the French Epidemiological Center for the Medical Causes of Death was used to calculate BD-related mortality rates and examine differences according to age and sex, determine underlying and non-underlying causes of death (UCD/NUCD), and compare with the general population (observed/expected ratios, O/E).
RESULTS: A total of 328 death certificates mentioned BD as UCD (n = 171) or NUCD (n = 157). The mean (± SD) age at death was 52.8 (± 11.3) years in men and 58.4 (± 16.5) in women (vs. 71.2 and 79.8 in the general population, respectively). The age-standardized mortality rate was 0.15/million person-years and significantly increased over the study period (p < 0.01). When BD was the UCD, the most frequent associated causes were infections (25.1%), underlying organ dysfunction (21.6%), and arterial events (15.2%). As compared to the general population, BD decedents < 45 years were more likely to die from a cardiovascular event (O/E = 6.25, p < 0.001); decedents > 45 years were more likely to die from infection (O/E = 9.69, p < 0.001). Between 1979 and 2016, BD as UCD decreases whereas NUCD increased.
CONCLUSION: This study found an earlier mean age at death for BD compared to the general population; young patients were more prone to die from cardiovascular complication whereas older patients died more frequently from infections. Over the years, the mean age at death increased and BD was less frequently considered as an UCD, suggesting a better knowledge of the disease and complications. Key Points • Patients with Behçet's disease die earlier than the general population. • Young patients were more prone to die from cardiovascular complication. • Older patients died more frequently from infections.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Behçet’s disease; Cardiovascular; Epidemiology; Infections; Mortality

Mesh:

Year:  2022        PMID: 35091777     DOI: 10.1007/s10067-021-06027-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

Review 1.  Behcet's disease: epidemiology, clinical manifestations, and diagnosis.

Authors:  Fereydoun Davatchi; Cheyda Chams-Davatchi; Hormoz Shams; Farhad Shahram; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahreh Faezi; Zahra Ghodsi; Bahar Sadeghi Abdollahi; Farimah Ashofteh; Negin Mohtasham; Hoda Kavosi; Mariam Masoumi
Journal:  Expert Rev Clin Immunol       Date:  2016-07-11       Impact factor: 4.473

2.  Incidence, prevalence, and mortality of Adamantiades-Behçet's disease in Korea: a nationwide, population-based study (2006-2015).

Authors:  Y B Lee; S Y Lee; J Y Choi; J H Lee; H S Chae; J W Kim; K D Han; Y G Park; D S Yu
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-10-12       Impact factor: 6.166

Review 3.  Major vessel involvement in Behçet's disease: an update.

Authors:  Kenneth T Calamia; Michael Schirmer; Melike Melikoglu
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

4.  Mortality in Behçet's disease.

Authors:  D Saadoun; B Wechsler; K Desseaux; D Le Thi Huong; Z Amoura; M Resche-Rigon; P Cacoub
Journal:  Arthritis Rheum       Date:  2010-09

5.  The natural course and factors affecting severity of Behçet's disease: a single-center cohort of 368 patients.

Authors:  Nilay Ugurlu; Selen Bozkurt; Ali Bacanli; Ayse Akman-Karakas; Soner Uzun; Erkan Alpsoy
Journal:  Rheumatol Int       Date:  2015-06-18       Impact factor: 2.631

6.  Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis.

Authors:  Yvan Jamilloux; Delphine Maucort-Boulch; Sébastien Kerever; Mathieu Gerfaud-Valentin; Christiane Broussolle; Mireille Eb; Dominique Valeyre; Pascal Seve
Journal:  Eur Respir J       Date:  2016-09-22       Impact factor: 16.671

Review 7.  Behçet's disease: New insights into pathophysiology, clinical features and treatment options.

Authors:  Antonio Greco; Armando De Virgilio; Massimo Ralli; Andrea Ciofalo; Patrizia Mancini; Giuseppe Attanasio; Marco de Vincentiis; Alessandro Lambiase
Journal:  Autoimmun Rev       Date:  2018-04-06       Impact factor: 9.754

Review 8.  Mortality in Behçet's syndrome.

Authors:  H Yazici; F Esen
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

9.  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Sarah Stewart; Kevin Chih Kai Yang; Kate Atkins; Nicola Dalbeth; Philip C Robinson
Journal:  Arthritis Res Ther       Date:  2020-02-13       Impact factor: 5.156

10.  A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.

Authors:  Timothy McEwan; Philip C Robinson
Journal:  Semin Arthritis Rheum       Date:  2020-12-17       Impact factor: 5.532

View more
  1 in total

Review 1.  Age-related immunosenescence in Behçet's disease.

Authors:  Döndü Üsküdar Cansu; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2022-05-20       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.